ABO2109
Non-Small Cell Lung Cancer NSCLC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Non-Small Cell Lung Cancer NSCLC cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
18f-alfatide Yantai LNC Biotechnology Singapore PTE. LTD. | Phase 3 | B |
Stro-004 Sutro Biopharma, Inc. | Phase 1 | CC |
ide892 IDEAYA Biosciences | Phase 1 | CC |
Tcr-T Cells Beijing Geekgene Technology Co., LTD | Phase 1 | CC |
Anti-Trop2 Car-Nk Cell Henan Cancer Hospital | Phase 1/2 | NR |
Same molecule, other indications
ABO2109 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →